SBIR-STTR Award

Multiplexed High Content Assay For Toxicity Mechanisms And Phenotypes In Live Ipsc Derived Cardiac Cells
Award last edited on: 10/24/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NIMHD
Total Award Amount
$229,893
Award Phase
1
Solicitation Topic Code
NIDA
Principal Investigator
Amanda M Gramlich

Company Information

Cairn Biosciences Inc

455 Mission Bay Boulevard South Suite 145
San Francisco, CA 94158
   (415) 269-2956
   info@cairnbio.com
   www.cairnbio.com
Location: Single
Congr. District: 12
County: San Francisco

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2016
Phase I Amount
$229,893
Toxicological assessments rely on low throughput costly animal studies that deliver minimal insights into compound toxicity mechanisms Induced pluripotent stem cells iPSCs are positioned to transform the evaluation of toxic compounds by enabling predictive physiologically relevant model systems compatible with high throughput screening Combining these iPSC benefits with high content screening approaches that enable diverse mechanistic and phenotypic readouts in living cells will deliver important new predictive toxicity evaluation capabilities The goal of this contract is to demonstrate the feasibility and benefits of this approach by delivering a novel multiplexed well plate format high content assay with distinct mechanistic stress response readouts and phenotypic organelle based reporters in iPSC derived cardiomyocytes Cairn will validate the assays response to tool compounds known to cause cardiotoxicity and demonstrate its compatibility with high throughput screening of at least samples day

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----